No abstract

We assessed the efficacy and safety of local nasal immunotherapy (LNIT) using an extract in macronized powder form of Parietaria pollen, a very important allergenic plant in the Mediterranean and other parts of the world. Twenty-six patients aged 13-37 years, with seasonal allergic rhinitis to this pollen, were enrolled in a double-blind placebo-controlled trial, carried out from autumn 1991 to the end of June 1992. They were selected on the basis of a positive skin-prick test, radioallergosorbent test (RAST) and intranasal challenge to Parietaria antigen. Patients were randomly divided into two groups of 13; the first group was given Parietaria antigen, and the second placebo. We recorded mean weekly symptom scores and drug consumption for 17 weeks during the pollen season in the year 1992, and specific serum-IgE and IgG levels. Three patients in the active group withdrew from the study because of bronchial symptoms. A significant difference was observed in mean weekly nasal symptom scores, in drug consumption and in specific nasal threshold to Parietaria allergenic extract in the treated and control groups. No difference was observed in serum IgE and IgG levels. Serum IgE levels rose significantly only in the control group after the pollen season. This study indicates that LNIT may be a useful alternative to traditional subcutaneous immunotherapy in patients with allergic rhinitis.

Our results suggest that allergic sensitization to horse allergens is more frequent than expected in urban-dwelling subjects without direct or occupational exposure to horses. Highly atopic individuals or individuals who are sensitized to common pet dander should undergo SPT and evaluation of serum specific IgE before starting activities involving regular contact with horses such as riding, and before entering environments associated with horses.

Allergy to Parietaria judaica pollen causes significant morbidity in many areas of the world. In addition to rhinitis, patients who are allergic to this pollen have a high incidence of asthma. The pollinating season is long, making this particular allergy challenging for clinicians to treat. This study was designed to determine if immunotherapy with an alum adsorbed partially purified Parietaria extract (Alpare Parietaria) containing a targeted maintenance dose of 12,500 BUs was effective in decreasing rhinitis symptoms in patients allergic to Parietaria. Using a double-blind placebo-controlled technique 36 patients received placebo or active extract for 2 years. Twenty (11 placebo and nine active) completed the 2 year study. Efficacy of treatment was evaluated by determining changes in skin reactivity, visual analog scores, diary symptom scores and end of study assessments. Reactions were monitored as well. Skin-test suppression was marginally significant in the actively treated group after 1 year and showed even more significant suppression after the second year. Nasal block, rhinorrhoea and sneezing all were significantly decreased in the active group. The nasal provocation test did not show a significant change after 1 year, in either group, but after 2 years of treatment the active group did show significant improvement. Although almost all patients in the actively treated group experienced local reactions, the incidence of systemic reactions was not different between the two groups. In conclusion, immunotherapy with this extract at this dose was effective in ameliorated rhinitis symptoms in patients allergic to Parietaria judaica.

No abstract

Because the pediatric age represents a good model to study the correlation between the exposure to allergens and development of respiratory allergy, we investigated the occurrence of a perennial type of symptomatology in children monosensitized to Olea europaea (O.e.) pollen allergens compared with subjects with monosensitization to Parietaria (P) and Gramineae (G) in order to confirm our previous observations in adults. We selected a group of 52 children with rhinitis and/or bronchial asthma and a SPT positivity only to pollens (30 to P, 15 to G, and 7 to O.e.). Using commercially available allergenic extracts and reagents, the following diagnostic procedures were performed: skin prick test (SPT), specific IgE assays (RAST), nonspecific bronchial provocation test (NsBPT) and specific nasal provocation test (sNPT), respectively, in patients with bronchial asthma and rhinitis. Pollen counts and a statistical analysis using Spearman's correlation test were also carried out. Six of seven children with monosensitization to O.e. allergens showed a perennial pattern of symptoms in comparison to 7 of 23 and 3 of 12, respectively, in subjects with P and G pollinosis. All patients with perennial nasal symptoms of O.e. group exhibited a late nasal response after sNPT. Although these findings on nasal response may partially explain the occurrence of a prolonged inflammation of the nose induced by O.e. allergens, we think that other possibilities could be investigated. In our opinion, further studies are necessary using better purified and standardized diagnostic materials and, moreover, a greater number of O.e. monosensitized children living in other geographical areas need to be examined for a comparison of our results with theirs.

No abstract

No abstract